Zidesamtinib, an investigational ROS1-selective inhibitor by Nuvalent, demonstrated meaningful clinical activity in heavily pre-treated ROS1-positive non-small cell lung cancer (NSCLC) patients, including those with CNS disease and resistance mutations like ROS1 G2032R. Data from the ARROS-1 trial showed objective response rates of 41-47% in patients previously treated with repotrectinib or taletrectinib, with notable intracranial responses. Preclinical studies also highlighted zidesamtinib's superior brain penetration and sustained intracranial efficacy compared to other ROS1 inhibitors. The FDA has accepted its New Drug Application with a target decision date of September 18, 2026, and Nuvalent plans a U.S. commercial launch later that year, potentially expanding use to TKI-naïve patients.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
